American College of Rheumatology (ACR) Convergence 2025

Oct 18, 2025
1 min read

Kali Therapeutics Announces Upcoming Poster Presentations at the American College of Rheumatology (ACR) Convergence 2025

Recent Posts

See All

Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress

SAN MATEO, CA. – June 08, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical da

Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress

SAN MATEO, CA. – May 12, 2026 – Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, announced that preclinical data for KT502, its second t

Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases

SAN MATEO, CA. – March 23, 2026 –Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license

Kali Therapeutics

Kali Therapeutics, Inc